Kiran Mazumdar-Shaw - Sep 12, 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Director, 10%+ Owner
Signature
/s/ Lara Meisner, Attorney-in-Fact
Stock symbol
BCAX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
4
Date filed
9/16/2024, 04:35 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Conversion of derivative security $0 +4.33M +3738.32% $0.00 4.44M Sep 16, 2024 By Biocon Limited F1, F2
transaction BCAX Common Stock Conversion of derivative security $0 +1.08M $0.00 1.08M Sep 16, 2024 By Biocon Pharma Inc. F1, F3
transaction BCAX Common Stock Conversion of derivative security $0 +325K $0.00 325K Sep 16, 2024 By Glentech International F1, F4
transaction BCAX Common Stock Conversion of derivative security $0 +433K $0.00 433K Sep 16, 2024 By Carica Investments F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Award $0 +23.7K $0.00 23.7K Sep 12, 2024 Common Stock 23.7K $18.00 Direct F6
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -40M -100% $0.00 0 Sep 16, 2024 Common Stock 4.33M By Biocon Limited F1, F2
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -9.99M -100% $0.00 0 Sep 16, 2024 Common Stock 1.08M By Biocon Pharma Inc. F1, F3
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -3M -100% $0.00 0 Sep 16, 2024 Common Stock 325K By Glentech International F1, F4
transaction BCAX Series Seed Redeemable Convertible Preferred Stock Conversion of derivative security $0 -4M -100% $0.00 0 Sep 16, 2024 Common Stock 433K By Carica Investments F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.
F2 Shares held by Biocon Limited ("Biocon Ltd"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 Shares held by Biocon Pharma Inc. ("Biocon Pharma"). The Reporting Person is the managing member of Biocon Pharma and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F4 Shares held by Glentech International ("Glentech"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F5 Shares held by Carica Investments ("Carica"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F6 The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.